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To date, the intracellular signaling pathways involved in dendritic cell (DC) function 
are poorly understood. The antioxidative transcription factor nuclear factor (erythroid- 
derived 2)-like 2 (Nrf2) has been shown to affect maturation, function, and subsequent 
DC-mediated T  cell responses of murine and human DCs. In experimental autoim-
mune encephalomyelitis (EAE), as prototype animal model for a T helper cell-mediated 
autoimmune disease, antigen presentation, cytokine production, and costimulation by 
DCs play a major role. We explore the role of Nrf2 in DC function, and DC-mediated 
T  cell responses during T  cell-mediated autoimmunity of the central nervous system 
using genetic ablation and pharmacological activation in mice and men to corroborate 
our data in a translational setting. In murine and human DCs, monomethyl fumarate 
induced Nrf2 signaling inhibits DC maturation and DC-mediated T cell proliferation by 
reducing inflammatory cytokine production and expression of costimulatory molecules. 
In contrast, Nrf2-deficient DCs generate more activated T helper cells (Th1/Th17) but 
fewer regulatory T cells and foster T cell proliferation. Transfer of DCs with Nrf2 activation 
during active EAE reduces disease severity and T cell infiltration. Our data demonstrate 
that Nrf2 signaling modulates autoimmunity in murine and human systems via inhibiting 
DC maturation and function thus shedding further light on the mechanism of action of 
antioxidative stress pathways in antigen-presenting cells.
Keywords: nuclear factor (erythroid-derived 2)-like 2/antioxidant response element signaling pathway, dendritic 
cells, inflammation, experimental autoimmune encephalomyelitis/multiple sclerosis, oxidative stress, antigen-
presenting cells
inTrODUcTiOn
In the periphery, immature dendritic cells (DCs) survey their environment and capture soluble anti-
gens, like microbes and cell debris. Since they are barely immunogenic, immature DC express only 
low levels of major histocompatibility complex (MHC) II and costimulatory molecules but display 
marked phagocytic capacity which renders them critical for maintaining peripheral T cell tolerance 
(1, 2). Activation of DC leads to maturation with increased surface marker expression and cytokine 
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production allowing them to efficiently present antigens to naive 
T cells (3, 4). Consequently, DC subsets and functions are altered 
in many autoimmune diseases including multiple sclerosis (MS), 
systemic lupus erythematosus or graft-versus-host disease (5–7). 
While DC maturation and corresponding changes in surface 
marker expression are well characterized (8), the involved intra-
cellular signaling pathways are less understood.
Recently, the antioxidant transcription factor nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2) was described as critical 
regulator responsible for maintenance of DC redox homeostasis, 
differentiation, and maturation by modulating the expression 
of cytoprotective genes, such as heme oxygenase 1 (Hmox1), 
NAD(P)H: quinone oxidoreductase 1 (Nqo1), and glutathione 
(9–12). In general, Nrf2 is involved in different aspects of cellular 
functions including differentiation, proliferation and inflamma-
tion by fostering antioxidative gene expression while suppressing 
the production of reactive oxygen species and proinflammatory 
cytokines as well as nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) signaling (13–17). Furthermore, aber-
rant function or expression of Nrf2 is associated with patholo-
gies such as inflammatory diseases, autoimmunity, cancer and 
neurodegeneration [as reviewed in Ref. (18, 19)]. In the cytosol, 
the activity of Nrf2 is tightly regulated via proteasomal degrada-
tion by Kelch-like ECH-associated protein 1 (Keap1) (20, 21). 
Appropriate stimuli, like oxidative stress, induce conformational 
changes in Keap1 allowing for translocation of Nrf2 into the 
nucleus where it binds to antioxidant response elements (ARE) 
and activates gene expression (21). Nrf2-deficient mice only toler-
ate mild autoimmune attacks, and if so they display an aggravated 
disease course in several inflammation-mediated animal models 
(22, 23), including experimental autoimmune encephalomyelitis 
(EAE) (24). In contrast, systemic activation of Nrf2 mitigates 
autoimmune inflammation in scurfy mice (25).
Fumaric acid esters, like dimethyl fumarate (DMF) and its pri-
mary active metabolite monomethyl fumarate (MMF), have been 
shown to activate the Nrf2-ARE pathway by altering the ability 
of Keap1 to interact with Nrf2 (26) and reduce DC maturation, 
cytokine release and T cell activation capacities mainly via NF-κB 
signaling pathways in vitro (27–31). In EAE, treatment with DMF 
led to significant therapeutic effects on parameters of inflamma-
tion and neurodegeneration (26, 32). Similar observations were 
made in MS clinical trials (33, 34). Thus, MMF or DMF treatment 
can be employed as an excellent model system to analyze effects 
of Nrf2 activation in DC.
Here, we focus on the effect of Nrf2 signaling on DC matura-
tion, function and subsequent T cell responses in vitro as well as 
in T cell-mediated autoimmunity of the central nervous system 
in vivo. We show that Nrf2 deficiency fosters a proinflammatory 
phenotype in murine and human DC, while Nrf2 activation pro-
motes rather tolerogenic functions by significantly modulating 
cytokine production and expression of costimulatory molecules.
MaTerials anD MeThODs
Mice
Nuclear factor (erythroid-derived 2)-like 2-fl/fl mice were a 
kind gift from Prof. Pi, China Medical University, Shenyang, 
China. CD11c-Cre mice were obtained from Prof. Steinkasserer, 
University of Erlangen-Nürnberg, Erlangen, Germany. Mice 
harboring a transgenic MOG-specific T cell receptor [2D2 mice 
(35)]; were a kind gift from Prof. V. Kuchroo, Boston, MA, USA. 
Wild-type (wt), 2D2, Nrf2KO, and CD11c-Cre/Nrf2-fl/fl mice 
were backcrossed on the C57BL/6J background and all mice were 
obtained from an in-house breed at the local animal care facility 
of the University of Erlangen-Nürnberg or the Ruhr-University 
Bochum under a 12-h day–night cycle and standardized envi-
ronment. All experiments were performed in accordance with 
the German laws for animal protection and were approved by 
local ethic committees (Government of Unterfranken, Bavaria, 
Germany, ref. # 55.2-2532-2-451).
Oral DMF gavage and eae induction
Mice received 15  mg/kg body weight DMF (Sigma-Aldrich, 
St. Louis, MO, USA) in 0.8 mg/ml hydroxypropyl methylcellulose 
(Sigma-Aldrich) twice daily by oral gavage, while control mice 
obtained 0.8  mg/ml hydroxypropyl methylcellulose. Mice were 
adapted to DMF treatment 2 weeks before EAE induction. Since 
the majority of DMF is rapidly metabolized to MMF by esterases 
in the intestine and only MMF can be detected in the systemic 
circulation (36, 37), we employed DMF to examine effects of Nrf2 
pathway activation in our in vivo studies but MMF for in vitro 
stimulation experiments.
Induction of active EAE was performed as previously 
described (38, 39). For DC transfer experiments, 1 ×  105 DC, 
cultured in  vitro for 10  days with or without 200  µM MMF 
(Sigma-Aldrich) and stimulated with 1 µg/ml lipopolysaccharide 
(LPS) (Sigma-Aldrich) for 24 h, were injected intraperitoneally 
at d2 and d7 after EAE induction together with 200 ng pertussis 
toxin (List Biological Laboratories).
generation of Murine Bone Marrow-
Derived Dc (BMDc)
Bone marrow cells were obtained from tibias and femurs and 
maintained in R10 medium (RPMI-1640 + 10% FCS + 1% peni-
cillin/streptomycin +  1% l-glutamine) containing granulocyte 
macrophage colony-stimulating factor (GM-CSF) (5  ng/ml, 
Biolegend, San Diego, CA, USA) and interleukin (IL)-4 (5 ng/ml, 
Biolegend) for 10  days with/without 200  µM MMF (Sigma-
Aldrich). Cells were matured on day 8 with 1 µg/ml LPS (Sigma-
Aldrich). For flow cytometry, cells were stained with αCD11c 
(N418, Biolegend), αCD80 (16-10A1, Biolegend), αCD86 (GL-1, 
Biolegend), and αMHCII (AF6-120.1, BD Biosciences, San Diego, 
CA, USA).
Dc Functional assays
Phagocytosis was assessed by stimulating DC with 1 µg/ml LPS 
(Sigma-Aldrich) for 48 h before adding opsonized Fluoresbrite® 
YG Carboxylate Microspheres 0.75  µm (Polysciences Inc., 
Warrington, PA, USA). After 20  h of incubation, cells were 
subjected to flow cytometry and phagocytic cells were detected 
in the FITC channel.
The migratory capacity of DC was investigated using a modi-
fied Boyden chamber assay and transwell inserts with a 5  µm 
porous bottom (Corning Life Sciences, Corning, NY, USA). 
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Mature DC were seeded into the migration chamber in medium 
containing 0.5% FCS. The lower chamber was supplemented 
with 10% FCS medium. After 20 h of migration, cells residing 
in the lower chamber (transmigrated fraction) were stained for 
CD11c and quantified by flow cytometry (FACSCantoII, BD 
Biosciences).
Murine coculture assays
Mature DC were loaded with MOG35–55 peptide (20 µg/ml) for 
1 h and seeded with naive transgenic T cells harboring a MOG 
specific TCR at a ratio of 1:6. Naive MOG-specific transgenic 
T cells were isolated form the spleen of 2D2 mice by magnetic 
activated cell sorting using the “Naive CD4+ T Cell Isolation 
Kit, mouse” according to the manufacturer’s instructions 
(Miltenyi Biotech, Bergisch Gladbach, Germany). For Th17 
differentiations, cocultured cells were additionally stimulated 
with IL-6 (40 ng/ml, R&D Systems, Minneapolis, MN, USA) and 
transforming growth factor beta (TGFβ1) (2 ng/ml, Biolegend). 
For Th1 differentiations, cells were cultured in the presence of 
IL-12p70 (20  ng/ml, R&D Systems) and anti-IL-4 (10  mg/ml, 
11B11, Biolegend). For Treg differentiations, TGFβ1 (10 ng/ml, 
Biolegend) was added to culture media. T cell frequencies were 
analyzed by flow cytometry (FACSCantoII, BD Biosciences) 
using the antibodies listed in the section “Murine FACS analysis.” 
To monitor proliferation, cells were pulsed with [3H]-thymidine 
24 h before analysis.
Murine T cell Differentiation
Differentiation of murine T  cells was performed as previously 
described (40). Splenic T cells were isolated by magnetic activated 
cell sorting using the “pan T  cell isolation kit II” according to 
the manufacturer’s instructions (Miltenyi Biotech). Cells were 
fluorescently stained with an antibody cocktail containing 
αCD4-FITC (RM4-5, eBioscience), αCD44-PE (IM7, Biolegend), 
αCD62L-APC (MEL-14, eBioscience), and αCD25-PE-Cy5 
(PC61.5, eBioscience) and were subsequently isolated by fluores-
cence activated cell sorting on MoFlo (Beckman-Coulter, Brea, 
CA, USA) in the FACS-core unit of the University Hospital 
Erlangen. Sorted naive T  cells (CD4+CD62L+CD44lowCD25−) 
were stimulated by plate-bound anti-CD3 (2 µg/ml, 145-2C11, BD 
Pharmingen, San Diego, CA, USA) and soluble anti-CD28 (2 µg/
ml, 37.51, BD Pharmingen) and cultured for 4 days in the pres-
ence of IL-6 (40 ng/ml, R&D Systems, Minneapolis, MN, USA) 
and TGFβ1 (2 ng/ml, Biolegend) for Th17, IL-12p70 (20 ng/ml, 
R&D Systems) and anti-IL-4 (10  µg/ml, Biolegend) for Th1 or 
TGFβ1 (10 ng/ml, Biolegend) alone for Treg differentiation. T cell 
frequencies were analyzed by flow cytometry (FACSCantoII, BD 
Biosciences) using the antibodies listed in the section “Murine 
FACS analysis.”
isolation of spinal cord lymphocytes
Spinal cords were disrupted with a 5 ml glass homogenizer fol-
lowed by Percoll (GE Healthcare) density gradient centrifugation. 
Cell frequencies were analyzed by flow cytometry (FACSCantoII, 
BD Biosciences) using the antibodies listed in the section “Murine 
FACS analysis.”
Murine Facs analyses
As previously described (40), dead cells were excluded by 
the fixable viability dye eFluor®780 (0.2  μl/test, eBioscience). 
Nonspecific Fc-mediated interactions were blocked by addition 
of 0.5  µl αCD16/32 (93, eBioscience). For surface staining, 
cells were treated with the respective fluorochrome-conjugated 
antibodies: αCD4-BV510 (RM4-5, Biolegend), αCD11c-FITC 
(HL3, BD Biosciences), αCD25-APC (PC61.5, eBioscience), 
αCD80-APC (16-10A1, Biolegend), αCD86-PerCP/Cy5.5 
(GL-1, Biolegend), and αMHCII-BV510 (M5/114.15.2, Biole- 
gend).
For intracellular cytokine staining, cells were stimulated for 
4 h with ionomycin (1 µM, Sigma-Aldrich) and PMA (50 ng/ml, 
Sigma-Aldrich) in the presence of monensin (2 µM, eBioscience), 
fixed with 1% paraformaldehyde and made permeable by sapo-
nin buffer treatment. Intracellular cytokines were stained with 
the respective fluorochrome-conjugated antibodies: αFoxp3-PE 
(FJK-16s, eBioscience), αIFNγ-APC (XMG1.2, eBioscience), 
and αIL-17A-PE (eBio17B7, eBioscience). Samples were meas-
ured with a flow cytometer (FACSCantoII, BD Biosciences).
generation of human Dcs
For the generation of monocyte-derived DCs from leukoreduc-
tion system chambers of healthy donors (HDs) the positive vote 
from the local ethics committee has been obtained (Re.-Nr.: 
4556). Generation of human monocyte-derived DC was 
performed as previously described (41). Peripheral blood 
mononuclear cells were prepared from leukoreduction system 
chambers of HDs by density centrifugation, followed by plastic 
adherence on tissue culture dishes (BD Falcon, San Diego, 
CA, USA). The non-adherent fraction was cryopreserved at 
−80°C for isolation of allogeneic T  cells as described before 
(42), while the adherent cell fraction was cultured for 4 days 
with or without 50 or 200 µM MMF in DC-medium consisting 
of RPMI 1640 (Lonza, Basel, Switzerland) supplemented with 
1% of heat-inactivated human serum type AB (Sigma-Aldrich), 
1% Penicillin/Streptomycin/l-glutamine (Sigma-Aldrich), and 
10 mM Hepes (Lonza) as well as 800 IU/ml (day 0) or 400 IU/ml 
(day 3) recombinant human GM-CSF and 250 IU/ml (days 0 
and 3) recombinant IL-4 (both Miltenyi). Maturation of DC 
was induced by adding a maturation cocktail consisting of 
200  U/ml IL-1β, 1,000  U/ml IL-6 (both CellGenix, Freiburg, 
Germany), 10  ng/ml tumor necrosis factor alpha (TNF-α) 
(Beromun, Boehringer Ingelheim, Germany), and 1 µg/ml PGE2 
(Prostin E2, Pfizer, NJ, NY, USA) for 48 h. DC were analyzed 
by flow cytometry for activation marker expression: αCD80-PE 
(2D10.4, eBioscience), αMHCII-PE/Cy5 (LN3, eBioscience), 
αCD25-FITC (M-A251, BD Biosciences), αCD86-PE (IT2.2, 
eBioscience), αMHCI-FITC (W6/32, eBioscience), αCCR7-
APC (3D12, eBioscience), αILT-4-FITC (27D6, eBioscience), 
and αCD83-PE (HB15e, eBioscience).
human Mixed lymphocyte reaction (Mlr)
Mature human DC were generated as described above (41) 
and were either left untreated or were stimulated with matura-
tion cocktail for 24  h. Allogeneic T  cells were generated from 
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cryopreserved non-adherent fraction. For this purpose, frozen 
cells were thawed, filtrated using a cell-strainer (Falcon) to 
remove dead cells and finally adjusted to 2 × 106 cells/ml in MLR 
medium consisting of RPMI 1640 (Lonza) supplemented with 
5% heat-inactivated human serum type AB (Sigma-Aldrich), 
1% Penicillin/Streptomycin/l-glutamine (Sigma-Aldrich), and 
10  mM HEPES (Lonza). Afterward, triplicates of 2 ×  105 allo-
geneic T cells were cocultured in 96-well flat cell culture plates 
(Falcon) with allogeneic DCs at different ratios for 72 h in MLR 
medium, and were finally pulsed with [3H]-thymidine (1 μC/well) 
for 8–16  h. Cultures were harvested onto glassfiber filtermates 
using an ICH-110 harvester (Inotech, Dottikon, Switzerland) and 
filters were counted in a 1450 microplate counter (Wallac, Turku, 
Finland).
cytometric Bead array
Determination of cytokines (IL-6, TNF-α) secreted by human 
DC and/or T cells into the supernatant was assessed by Human 
Inflammation LEGENDplex™ (13-plex, Biolegend) according to 
the manufacturer’s protocol.
enzyme-linked immunosorbent  
assay (elisa)
Cytokine concentrations in murine cell culture supernatants 
were analyzed by ELISA for the secretion of IL-6, TNF-α, IL-23, 
and IL-12 (R&D Systems) according to the manufacturer’s 
instructions.
real-time Pcr
RNA isolation, reverse transcription and PCR reactions were 
performed as previously described (40). Relative quantification 
was performed by the ΔΔCT method, normalizing target gene 
expression on actb/β-Actin or gapdh as housekeeping gene. 
The following TaqMan® real-time PCR assays from Thermo 
Fisher Scientific were used: actb (β-Actin) Mm00607939_s1, 
nfe2l2 (nrf2) Mm00477784_m1, il6 Mm99999064_m1, nqo1 
Mm01253561_m1, hmox1 Mm00516005_m1, il10 Mm01288386_
m1, il12a Mm00434169_m1, arg1 Mm00475988_m1, tgfb 
Mm01178819_m1, nqo1 Hs02512143_s1, akr1c1 Hs04230636_sH, 
hcar2 Hs02341584_s1, and gapdh Hs02758991_g1.
Western Blot
Cultured cells were harvested in 1× Ripa lysis buffer [15  mM 
NaCl, 3.85  mM SDS, 5  mM Tris, 13.4  mM SDOX, 0.05  mM 
EDTA, 0.1% NP40, complete protease inhibitor cocktail 
Complete Mini and phosphatase inhibitor cocktail PhosStop 
(Roche Diagnostics, Basel, Switzerland)]. Protein concentration 
was determined using the BC Assay Protein Quantitation Kit 
(Interchim, Montluçon, France). Protein was detected using 
a rabbit polyclonal Nqo1 antibody (1:1,000, ab34173, Abcam, 
Cambridge, United Kingdom). Mouse anti-β-Actin (1:1,000) was 
obtained from Abcam (ab8226). Donkey antirabbit Alexa Fluor 
488-conjugated and goat antimouse Alexa Fluor 647-conjugated 
secondary antibodies (1:1,000, Invitrogen, Carlsbad, CA, USA) 
were used. Detection was performed using a Fusion Capt Advance 
FX7 (peqlab, Erlangen, Germany).
statistical analysis
Statistical testing was performed using GraphPad Prism 
(GraphPad Software Inc., San Diego, CA, USA). All in vitro and 
ex vivo data were analyzed by either one-/two-way ANOVA 
followed by Tukey’s posttest, unpaired t-test or Mann–Whitney 
test after checking for normal distribution (unless otherwise 
indicated). EAE data were analyzed by Mann–Whitney U-test. 
Data are presented as mean ±  SEM; *p <  0.05, **p <  0.01, or 
***p < 0.001 were considered to be statistically significant.
resUlTs
nrf2 signaling alters Dc activation and 
Maturation In Vitro
To analyze Nrf2 signaling in DC, we employed Nrf2-deficient 
cells. In a complementary approach, MMF treatment was used 
to induce Nrf2 signaling in DC. BMDC were cultured with 
200 µM MMF either from the beginning (day 0) or starting at 
the day of LPS stimulation (i.e., day 8) to analyze if the time point 
of Nrf2 activation is crucial for its effect on DC maturation and 
surface marker expression. First, we examined whether activa-
tion of Nrf2-dependent signaling pathways influences BMDC 
generation in vitro. Yet CD11c+ cell frequencies were not altered 
in MMF-treated cell cultures (Figure 1A). However, the expres-
sion of MHCII, CD80 and CD86 was reduced when BMDC were 
generated under Nrf2 activating conditions (day 0) whereas 
addition of MMF on day 8 together with LPS, had almost no 
effect on activation marker expression (Figure 1B; Figure S1A in 
Supplementary Material).
To investigate whether the effect of MMF on BMDC surface 
marker expression is indeed dependent on Nrf2 induced signal-
ing pathways, we treated Nrf2-deficient BMDC generated from 
either complete Nrf2 knockout mice (Nrf2KO) or conditional 
DC specific knockout mice (CD11c-Cre/Nrf2-fl/fl) with MMF. 
Again, the yield of CD11c+ cells did not differ between bone 
marrow obtained from wt, Nrf2KO, or CD11c-Cre/Nrf2-fl/fl 
mice and treatment with 200  µM MMF did not influence the 
generation of BMDC in the cell culture (Figure 1C). However, 
flow cytometric analyses revealed enhanced expression of CD80, 
CD86 (Figure  1D), and CD40 (Figure S1B in Supplementary 
Material) on Nrf2-deficient BMDC generated from either 
Nrf2KO or CD11c-Cre/Nrf2-fl/fl mice compared to wt BMDC. 
Additionally, MMF treatment had no influence on the frequency 
of CD80+/CD86+ and CD80+/CD40+ Nrf2-deficient BMDC but 
reduced the expression of CD80, CD86, and CD40 on wt BMDC 
(Figure 1D; Figure S1B in Supplementary Material).
In conclusion, modulation of the Nrf2 signaling pathway criti-
cally affects the activation status of DC in vitro.
nrf2 affects Dc Functionality and 
cytokine expression Profile
Next, we assessed the influence of Nrf2 on different essential 
BMDC functions in  vitro. As shown in Figure  2A, migratory 
capacities of BMDC isolated from Nrf2KO mice was significantly 
increased compared to BMDC from wt mice. Furthermore, MMF-
treated wt BMDC showed a strongly reduced migratory capacity 
FigUre 1 | Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) signaling alters dendritic cell (DC) activation status. (a) Frequency of CD11c+ cells after generating (d0) 
or just activating (d8) bone marrow-derived DC (BMDC) in the presence of 200 µM metabolite monomethyl fumarate (MMF) (data pooled from three to five 
experiments). (B) Expression of CD80, CD86, and MHCII on cultured CD11c+ BMDC after MMF treatment as assessed by flow cytometry (data pooled from three to 
four experiments, *p < 0.05, **p < 0.01). (c) Frequency of CD11c+ cells after generating wild-type (wt), Nrf2KO, and CD11c-Cre/Nrf2-fl/fl BMDC in the presence of 
200 µM MMF (data pooled from four independent experiments). (D) Frequency of CD80+CD86+ cells in CD11c+ BMDC generated from wt, Nrf2KO, and CD11c-
Cre/Nrf2-fl/fl mice under MMF treatment as assessed by flow cytometry (data pooled from four experiments, *p < 0.05, **p < 0.01, ***p < 0.001). BMDC were 
stimulated with 1 µg/ml LPS for 48 h before analysis. LPS stimulated, but otherwise treatment naive BMDC obtained from wt mice served as control.
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compared to untreated wt mice (Figure  2A). The phagocytosis 
rate of MMF-treated wt BMDC was not altered compared to 
untreated wt BMDC but decreased in Nrf2-deficient BMDC which 
correlates well with their enhanced maturation status (Figure 2B).
Expression analysis revealed that MMF treatment enhanced 
Nrf2 mRNA levels (Figure  2C) in wt BMDC in  vitro. In turn, 
Nrf2 activation not only induced its antioxidative target genes 
nqo1 and hmox1 but also the anti-inflammatory cytokine il10 
(Figures  2D–F). As expected, nfe2l2 (Nrf2), nqo1, and hmox1 
expression was almost undetectable in Nrf2-deficient BMDC 
and tgfb expression levels were also significantly lower compared 
to wt BMDC (Figures  2C–E,G; Figure S2 in Supplementary 
Material). Furthermore, Nrf2 activation enhanced, while Nrf2 
deficiency reduced, the expression of arginase 1 (arg1), a marker 
for tolerogenic DC (Figure  2H). Nrf2KO BMDC displayed a 
higher expression level of il12a compared to wt BMDC, while Nrf2 
activation decreased proinflammatory cytokine expression on the 
mRNA level (Figures 2I,J). Nrf2 induction significantly reduced 
the production of IL-6, IL-12, IL-23, and TNF-α, proinflammatory 
cytokines that mediate T helper (Th)1 and Th17 differentiation, 
in wt but not Nrf2KO (data not shown) or CD11c-Cre/Nrf2-fl/
fl BMDC (Figures 2K–N). Furthermore, Nrf2-deficient BMDC 
tended to produce higher baseline proinflammatory but lower 
tolerogenic cytokine levels compared to wt cells (Figure 2).
Immunoblot analysis of Nqo1 protein in wt and Nrf2-deficient 
BMDC cultures confirmed that the induction of Nqo1 expression 
in BMDC by MMF treatment is Nrf2 dependent (Figure  2O; 
Figure S3 in Supplementary Material).
Taken together, these data indicate that Nrf2 signaling alters DC 
functionality by modulating maturation, migration, expression of 
costimulatory molecules, and cytokine/chemokine production, 
which are required for effective antigen presentation to T cells.
nrf2 Directly and indirectly regulates  
T cell Differentiation and Proliferation
In coculture experiments, untreated or MMF pretreated wt and 
Nrf2KO BMDC were cultured together with naive CD4+ T cells 
FigUre 2 | Continued
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FigUre 2 | Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) affects functionality of myeloid dendritic cell(DC). (a) Migratory capacity of Nrf2KO and metabolite 
monomethyl fumarate (MMF)-treated wild-type (wt) bone marrow-derived DC (BMDC) compared to control cells as assessed by an in vitro FCS-gradient Transwell 
assay (data pooled from two to five independent experiments, **p < 0.01, ***p < 0.001). (B) Phagocytic capacity of MMF versus control-treated wt and Nrf2KO 
BMDC determined as frequency of fluorescent bead uptake by flow cytometry (data pooled from two to four experiments, **p < 0.01, ***p < 0.001). (c–J) Gene 
expression analysis of nfe2l2 (Nrf2) (c), nqo1 (D), hmox1 (e), il10 (F), tgfb (g), arg1 (h), il6 (i), and il12a (J) in MMF-treated wt and Nrf2-deficient BMDC compared 
to control cells (data pooled from two to three preparations, *p < 0.05, **p < 0.01, ***p < 0.001). (K–n) Interleukin (IL)-6 (K), IL-12 (l), IL-23 (M), and tumor 
necrosis factor alpha (n) production in MMF-treated wt and Nrf2-deficient cultured BMDC (n = 6 for wt and n = 3 for CD11c-Cre/Nrf2-fl/fl, *p < 0.05, **p < 0.01, 
***p < 0.001). (O) Representative immunoblot of NAD(P)H: quinone oxidoreductase 1 (Nqo1) protein expression in wt and Nrf2-deficient BMDC cultured with and 
without MMF. β-Actin was used as loading control.
FigUre 3 | Nuclear factor (erythroid-derived 2)-like 2 (Nrf2Nrf2) shows direct and indirect effects on T cell differentiation. (a–c) MOG-loaded, metabolite 
monomethyl fumarate (MMF) pretreated or untreated wt and Nrf2KO bone marrow-derived dendritic cell (BMDC) were cocultured with MOG-specific transgenic 
naive CD4+ T cells under Th1 (a), Th17 (B), or Treg (c) cell polarizing conditions (data pooled from three to six experiments, *p < 0.05, **p < 0.01). (D) Proliferation 
rate of T cells cultured with Nrf2KO or MMF pretreated or untreated wild-type (wt) BMDC as assessed by thymidine incorporation assay (one out of three 
representative experiments is shown, ***p < 0.001, cpm = counts per minute). (e–g) Addition of 200 µM MMF to wt and Nrf2KO CD4+ T cell differentiation culture 
under Th1 (e), Th17 (F), or Treg (g) polarizing conditions (data pooled from three to five experiments, **p < 0.01).
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under Th1, Th17, or Treg cell polarizing conditions to demon-
strate effects of Nrf2 signaling on DC-mediated T cell activation. 
Nrf2-deficient BMDC increased Th1 and Th17 but reduced Treg 
differentiation in coculture (Figures  3A–C). MMF pretreat-
ment of wt BMDC had no effect on Th1 and Th17 frequencies 
(Figures 3A,B) but increased Treg differentiation (Figure 3C). 
Thymidine incorporation showed an enhanced proliferation rate 
of T cells that were cultured together with Nrf2KO BMDC and 
a reduced proliferation in the coculture with MMF pretreated wt 
BMDC (Figure 3D).
T  cell monocultures demonstrated that Nrf2 had no direct 
effect on Th1 and Th17  cell differentiation (Figures  3E,F). 
However, Nrf2 deficiency induced a distinct reduction in Treg 
differentiation (Figure 3G).
These results show that Nrf2 signaling in DC may modulate 
their potential to regulate T cell differentiation and proliferation.
FigUre 4 | Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) signaling alters disease course and immune cell activation in the experimental autoimmune 
encephalomyelitis (EAE) mouse model. (a–c) Ex vivo flow cytometry analysis of CD11c+ cells (a) as well as CD80/CD86 (B) and MHCII (c) expression in the spinal 
cord under dimethyl fumarate (DMF) versus control treatment on day 14 after active EAE induction (n = 3–4 mice per group, *p < 0.05). (D) Clinical course of 
MOG35–55 EAE after dendritic cell (DC)-transfer. Untreated or metabolite monomethyl fumarate (MMF) pretreated in vitro cultured bone marrow-derived DC (BMDC) 
were transferred into EAE mice on days 2 and 7 after MOG immunization. Data are shown on a 5-point score scale (n = 9 mice per group, data pooled from two 
independent experiments, *p < 0.05). (e) Ex vivo flow cytometry analysis of total CD4+, Th1, and Th17 cells in the spinal cord of DC-transferred mice at the 
maximum of disease (n = 7–8 mice per group, data pooled from two independent experiments, *p < 0.05).
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nrf2 influences Disease course and 
immune cell activation in the eae  
Mouse Model
To demonstrate the relevance of the Nrf2 pathway in DC function 
for T cell-mediated autoimmunity in vivo, we employed the EAE 
animal model.
Spinal cords of DMF or control-treated wt and Nrf2KO mice 
were analyzed for DC frequencies and surface marker expression 
on day 14 after MOG-EAE induction (Figures 4A–C). Neither 
Nrf2 activation nor deficiency had an effect on the frequency 
of CD11c+ cells in the spinal cord of EAE mice (Figure 4A). In 
good accordance with the previous data, Nrf2 deficiency caused 
a significant increase in the expression of the activation markers 
CD80 and CD86 and enhanced MHCII expression on CD11c+ 
DC in the spinal cord (Figures 4B,C).
To further elucidate the effect of Nrf2 modulation on DC 
function during neuroinflammation, we employed MMF treat-
ment as a potent Nrf2 inducer. In vitro cultured untreated or 
MMF-treated BMDC were injected into untreated wt mice at d2 
and d7 after EAE induction. Mice which received MMF-treated 
BMDC showed an ameliorated clinical disease course compared 
to the control group (Figure 4D) and also a significantly reduced 
amount of total CD4+ as well as Th1 and Th17 cells in the spinal 
cord (Figure 4E).
Therefore, Nrf2 induction in DC in  vitro may promote a 
tolerogenic phenotype enabling these cells to mitigate active EAE 
in vivo.
nrf2 signaling alters Maturation status, 
gene expression Profile, and T cell 
activation capacity of human Dc In Vitro
In a next step, we translated our findings from murine to human 
DC. Treatment of in  vitro cultured human monocyte-derived 
DC with increasing amounts of the potent Nrf2 inducer MMF 
caused a concentration-dependent reduction of DC costimula-
tory, activation and inflammatory molecules including CD80, 
CD86, MHCI, MHCII, CD25, CD83, and C-C chemokine recep-
tor type 7 (CCR7) as well as an increased expression of the tolero-
genic surface receptor Ig-like transcript (ILT)-4 (Figures 5A–H).
Expression analysis showed that Nrf2 activation enhanced 
the expression of nqo1 and aldo-keto reductase family 1 member 
C1 (akr1c1) in human monocyte-derived DC analogously to 
murine BMDC (Figures 6A,B). Furthermore, MMF induced the 
expression of hydroxycarboxylic acid receptor 2 (hcar2), a niacin 
receptor involved in the regulation of inflammation and oxidative 
stress independently from Nrf2 signaling (Figure 6C). Human 
DC-treated with MMF also exhibited reduced tnfa and il6 but 
increased il10 and tgfb expression compared to the control group 
(Figures 6D–G).
Thymidine incorporation revealed a robust reduction in the 
T cell proliferation rate when T cells were cultured together with 
MMF pretreated human monocyte-derived DC compared to 
untreated DC (Figure 6H). To verify our PCR results on the pro-
tein level, cytokine production was measured in the supernatant 
of the aforementioned coculture assays. Here, IL-6 (Figure 6I) 
FigUre 5 | Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) affects maturation marker expression of human dendritic cell (DC) in vitro. Frequency of CD80 (a), CD86 
(B), MHCI (c), MHCII (D), CD25 (e), CD83 (F), CCR7 (g), and ILT-4 (h) positive cells in total human monocyte-derived DC under metabolite monomethyl fumarate 
(MMF) treatment as assessed by flow cytometry. The immature control group was not treated with the maturation cocktail as described in the method section. 
Statistical significance was tested between the matured, untreated control group (ctrl) and the MMF-treated groups (data pooled from four to five independent 
experiments, *p < 0.05, **p < 0.01, ***p < 0.001).
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and TNF-α (Figure 6J) secretion was significantly reduced when 
DC were pretreated with MMF.
Complementary to the murine model, induction of Nrf2 
signaling in human monocyte-derived DC modulates maturation 
marker expression, cytokine production and DC induced T cell 
proliferation.
DiscUssiOn
Here, we show that Nrf2 signaling plays a pivotal role for effects 
of fumarates on DC maturation, function and their capacity to 
regulate T  cell responses in autoimmunity in mice and men. 
While DC specific Nrf2 deletion induces immunogenic DC 
with high costimulatory potential, activation of the Nrf2 signal-
ing pathway via fumarates rather generates immature DC which 
show reduced proinflammatory gene and cytokine expression 
but enhanced tolerogenic properties also in  vivo. Effects of 
fumarates on Nrf2 activation and on DC as well as a role of the 
Nrf2 pathway in murine and human DC have been described 
previously (15, 26, 29, 43, 44). Our study now links these obser-
vations and shows functional effects of fumaric acid esters on 
DC via the Nrf2 pathway as novel significance beyond what is 
already published.
In previous studies utilizing in vitro DC cultures, treatment 
with fumaric acid esters in murine and human systems retains DC 
in a rather immature, inactive state and reduces proinflammatory 
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gene and cytokine expression (27, 28). We now extend these find-
ings and show that fumaric acid esters activate the Nrf2 signaling 
pathway in DC thereby fostering anti-inflammatory properties 
in a time- and concentration-dependent manner. Furthermore, 
Nrf2 modulates DC-mediated T cell proliferation and differen-
tiation specifically favoring the induction of regulatory T cells. 
The observed decrease in IL-12 production and enhanced secre-
tion of IL-10 in our murine and human DC cultures after Nrf2 
activation may be an explanation for the induction of anergy and 
tolerance in T cells (45).
Several groups employed Nrf2KO mice to demonstrate the 
relevance of Nrf2 signaling in DC biology in vitro (15, 17). We 
complement these data revealing that DC specific Nrf2 deletion 
generates strongly immunogenic DC that express high levels of 
costimulatory molecules. Nrf2-deficient DC also display marked 
migratory potential but low phagocytic capacity which renders 
them critical for stimulating peripheral T cell responses.
In MS and EAE as a prototype model for T  cell-mediated 
autoimmunity, a beneficial effect of Nrf2 activation via DMF has 
already been shown (26, 46). Yet, these reports did not focus on 
DC and previous studies on the impact of fumaric acid esters on 
DC function mainly comprise in vitro data (28, 29). We utilized 
EAE in C57BL/6J mice as model to determine whether Nrf2 
signaling in DC is also crucial for regulating autoreactive T cell 
responses in vivo. In the acute phase of EAE, the expression of 
costimulatory markers on CNS infiltrating DC is enhanced in 
Nrf2KO mice. Furthermore, injection of MMF pretreated DC 
shortly after EAE induction ameliorates the disease course and 
reduces the number of spinal cord infiltrating Th1 and Th17 cells. 
Therefore, the reported effects of fumarates on T  cell popula-
tions may be rather indirect or in the case of lymphopenia even 
cytotoxic (32). Our data not only support the in vitro observation 
that Nrf2 induces immature, tolerogenic DC but also prove that 
the effect of Nrf2 signaling on DC function is critical enough 
FigUre 6 | Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) alters the expression profile and functionality of human dendritic cell (DC). (a–g) Gene expression 
analysis of nqo1 (a), akr1c1 (B), hcar2 (c), tnfa (D), il6 (e), il10 (F), and tgfb (g) in untreated and metabolite monomethyl fumarate (MMF)-treated human monocyte-
derived DC (data pooled from four preparations, *p < 0.05, **p < 0.01, ***p < 0.001). (h) Proliferation rate of allogeneic T cells cultured with MMF pretreated or 
untreated human monocyte-derived DC as assessed by thymidine incorporation assay (data pooled from four independent experiments, **p < 0.01, ***p < 0.001 
compared to ctrl, cpm = counts per minute). (i–J) Interleukin (IL)-6 (i) and tumor necrosis factor alpha (TNFα) (J) secretion by MMF pretreated or untreated human 
monocyte-derived DC measured in the supernatant of T cell-DC coculture assays normalized to immature DC (data pooled from three independent experiments, 
*p < 0.05).
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